search
for
 About Bioline  All Journals  Testimonials  Membership  News  Donations


Revista Colombia Médica
Universidad del Valle - Facultad de Salud
ISSN: 0120-8322
EISSN: 1657-9534
Vol. 37, No. 4, 2006, pp. 258-265
Bioline Code: rc06054
Full paper language: Spanish
Document type: Research Article
Document available free of charge

Revista Colombia Médica, Vol. 37, No. 4, 2006, pp. 258-265

 en Liver and haematological safety of amodiaquine treatment in non-complicated falciparum malaria
Juan Gabriel Piñeros, Mary Luz López, Jaime Carmona-Fonseca, Silvia Blair

Abstract

Background: At present there are few effective antimalarial drugs, amodiaquine is one of them; however, its use has been restricted by previous information about hematic and hepatic toxicity when it is administered as prophylactic at doses greater than 1,500 mg. But at therapeutic doses, the side effects are either slight or of moderate intensity and include nausea, vomit and pruritus.
Objective: To evaluate the hepatic and hematic toxicity of amodiaquine administered at doses and time recommended for treatment of uncomplicated Plasmodium falciparum check for this species in other resources malaria.
Methods: Longitudinal design with no blind determination of the effect. A total of 57 patients were included and followed up for 10 days (clinical-parasitological evaluation).
Results: Hematic and hepatic variables showed slight alteration previous treatment and were normal postreatment. Therapeutic efficacy of amodiaquine was 100%. All variables were normal at days 5 and 10, suggesting absence of toxic effects imputable to amodiaquine. The side effects were few, slight and disappeared completely at day 10.
Conclusions: Amodiaquine administered at doses (25 mg/kg weight) and time (3 days) established for treatment of uncomplicated Plasmodium falciparum malaria is safe, it did not show neither hematic nor hepatic toxicity.

Keywords
Amodiaquine; Hepatotoxicity; Hematotoxicity; Malaria; Plasmodium falciparum .

 
 es Seguridad hepática y hemática de la amodiaquina en el tratamiento de la malaria no complicada por Plasmodium falciparum check for this species in other resources
Juan Gabriel Piñeros, Mary Luz López, Jaime Carmona-Fonseca, Silvia Blair

Resumen

Introducción: Actualmente existe un número limitado de antimaláricos eficaces, entre ellos amodiaquina; sin embargo, su uso se ha restringido por informes previos de toxicidad hepática y hemática a dosis superiores a 1,500 mg administradas como profiláctico para malaria. No obstante, en dosis terapéuticas antimaláricas los efectos adversos son de intensidad leve o moderada, e incluyen náuseas, vómito y prurito.
Objetivo: Evaluar la toxicidad hepática y hemática de la amodiaquina en dosis y tiempo establecidos para tratar la malaria por Plasmodium falciparum check for this species in other resources no complicada.
Metodología: Diseño longitudinal con determinación no ciega del efecto. Se captaron 57 pacientes, seguidos por 10 días (evaluación clínico-parasitológica).
Resultados: Antes del tratamiento, las variables hemáticas y hepáticas mostraron alteración leve y se normalizaron postratamiento, que fue 100% eficaz. Los días 5 y 10 del tratamiento todas las variables estaban normales, lo que sugiere ausencia de efectos tóxicos imputables al medicamento. Los efectos adversos fueron pocos, leves y desaparecieron completamente el día 10.
Conclusiones: Usada en la dosis (25 mg/kg peso) y el tiempo (3 días) definidos para el tratamiento de la malaria por P. falciparum sin complicaciones, la amodiaquina no mostró efectos adversos ni toxicidad hepática ni hemática.

Palabras-clave
Amodiaquina; Hepatotoxicidad; Hematotoxicidad; Malaria; Plasmodium falciparum.

 
© Copyright 2006 - Revista Colombia Médica
Alternative site location: http://colombiamedica.univalle.edu.co

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2017, Site last up-dated on 16-Oct-2017.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Internet Data Center of Rede Nacional de Ensino e Pesquisa, RNP, Brazil